"Asian Eye Institute is a world-class eye institute that puts the Philippines on the map of quality health care. Established in 2001, the institute is at the forefront of efforts to make breakthrough technologies for eye care treatment available to all patients. It serves 60,000 local and foreign patients annually. Asian Eye provides a full range of specialized medical services, including treatment and management of cataract, glaucoma, diabetic retinopathy, macular degeneration, uveitis, strabismus, and cornea and external diseases; LASIK; eye plastic surgery; pediatric ophthalmology and optometry; ocular genetics; low vision and visual rehabilitation; optical dispensary and contact lens services."

During the past decade, Asian Eye Institute conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 7 clinical trials were completed, i.e. on average, 38.9% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 5 clinical trials were completed. i.e. 55.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Asian Eye Institute" #1 sponsor was "Allergan" with 5 trials, followed by "Beaver-Visitec International, Inc." with 5 trials sponsored, "Bausch & Lomb Incorporated" with 4 trials sponsored, "AcuFocus, Inc." with 3 trials sponsored and "ACE Vision Group, Inc." with 3 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Asian Eye Institute" #1 collaborator was "targomedGmbH" with 2 trials as a collaborator, "Ivantis, Inc." with 1 trials as a collaborator and "Tigermed Consulting Co., Ltd" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Asian Eye Institute" are "Cataract" (10 trials), "Presbyopia" (8 trials), "Lens Opacities" (5 trials), "Ametropia" (2 trials) and "Ocular Hypertension" (2 trials). Many other conditions were trialed in "Asian Eye Institute" in a lesser frequency.

Most popular intervention types in "Asian Eye Institute" are "Device" (15 trials), "Drug" (7 trials), "Procedure" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "IOL implantation experimental" (4 trials), "IOL implantation active comparator" (2 trials), "2.0 mg DE-122 Injectable Solution + Lucentis" (1 trials), "4.0 mg DE-122 Injectable Solution + Lucentis" (1 trials) and "AGN-195263" (1 trials). Other intervention names were less common.

The vast majority of trials in "Asian Eye Institute" are 24 trials for "All" genders.

Currently, there are NaN active trials in "Asian Eye Institute". undefined are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Asian Eye Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Asian Eye Institute, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 14 trials that are defined as “Not Applicable".